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ABSTRACT 
Purpose: To measure the impact of a multidisciplinary one-stop follow-up 
clinic (MDOSC) on breast and ovarian surveillance, risk reducing surgery and 
enrolment in clinical trials in BRCA1/2 carriers.  
Patients and Methods: All BRCA1/2 carriers in our region were invited and 
chose which specialists to see in our MDOSC offering best practice using 
clinical protocols based on national guidelines and published data. Uptake 
was evaluated over 24 months recording numbers of individuals undergoing 
breast and ovarian surveillance, risk reducing surgery, newly diagnosed 
cancers, their method of detection and participation in clinical trials. 
Results: 172 (60%) of invited BRCA1/2 carriers chose to attend the MDOSC. 
Breast surveillance was initiated in 88% and screening frequency altered in 
14% of women to comply with national guidelines. Risk reducing salpingo-
oophorectomy was chosen by 47% of women and an additional 39% were 
considering it. The rate of failure to remove fallopian tubes fell from 15% to 
3% of procedures (p<0.01) and peritoneal washings and serial sectioning of 
tubes and ovaries rose from 25% and 14% before, to 67% (p<0.001) and 63% 
(p<0.001) procedures respectively, after initiation of our MDOSC. 24% of 
women considered and 18% decided to undergo risk reducing mastectomy 
during the follow-up period. Participation in clinical trials increased significantly 
from 51 to 229 enrolments (p<0.001).  
Conclusions: Our novel MDOSC designed to devise an individually tailored 
cancer risk management strategy had a high uptake amongst our BRCA1/2 
carriers. Attendance resulted in improved breast and ovarian cancer risk 
management. 
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BACKGROUND 
About 5% of breast and ovarian cancers are caused by germline mutations in 
high risk cancer susceptibility genes such as BRCA1 and BRCA2 Slattery (1), 
Colditz et al (2). Individuals with a mutation in the BRCA1 or BRCA2 gene 
have an up to 80% lifetime risk of developing breast cancer and an up to 45% 
lifetime risk of developing ovarian cancer Easton et al (3). Males with a 
BRCA2 mutation have an up to 6% lifetime risk of breast cancer and an up to 
14% lifetime risk of prostate cancer. Individuals and families with an inherited 
predisposition to breast and ovarian cancer due to a BRCA1/BRCA2 mutation 
face many challenges such as coming to terms with a highly increased breast 
and ovarian cancer risk, facing complex decisions regarding surveillance and 
risk reducing options, deciding how to communicate the possibility of inherited 
cancer risk to their offspring and keeping up with newest research 
developments. 
 
PATIENTS AND METHODS 
A 24 month “New Services and Innovations in Healthcare” grant from Guy’s 
and St Thomas Charity was obtained to establish an MDOSC for BRCA1/2 
carriers. The aims of the MDOSC are summarized in Table 1. The MDOSC 
was run once a month. BRCA1/2 carriers in our region of Southeast London, 
Kent and East Sussex received an invitation letter. All individuals attending 
the MDOSC were seen by a genetic health care professional but could 
choose which specialists (Breast Surgeon, Gynaecologist, Oncologist, 
Psychologist and Research Nurse) to see. Breast and ovarian surveillance 
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results and histology reports of any risk reducing procedures or cancers were 
obtained before each clinic to inform the discussion at the multidisciplinary 
meeting preceding the MDOSC where an individually tailored counseling and 
management strategy was devised for each patient. Patients were allocated 
personal consecutive 30-minute appointments with each clinician they chose 
to see and informed on how long to expect to attend the MDOSC depending 
on the number of health care professionals they decided to see. Careful 
scheduling of all appointments and coordination of the MDOSC on the day by 
the clinic coordinator enabled the MDOSC to run smoothly without delays. 
 
Participating health care professionals covered the following topics: Genetic 
health care professionals covered genetic issues such as cascade testing, 
prenatal testing, pre-implantation genetic diagnosis as well as breast 
surveillance. Gynaecological health care professionals covered ovarian 
surveillance, risk reducing salpingo-oophorectomy (RRSO), contraception, 
hormonal replacement therapy (HRT), prenatal and pre-implantation genetic 
diagnosis. Breast surgeons covered risk reducing and reconstructive options 
and the oncologist covered the nature of prior or planned oncology 
treatments, treatment trials and chemoprevention. The research nurse 
discussed all trials that individuals were eligible for. The psychologist 
discussed any issues raised by individuals attending the MDOSC and 
counselled women contemplating risk reducing mastectomies. 
 
The MDOSC infrastructure, assuring interaction of all the relevant medical 
specialties offered best practice based on the National Institute of Health and 
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Clinical Excellence (NICE) guidelines “The classification and care of women at 
risk of familial breast cancer in primary, secondary and tertiary care”(4).  
 
The NICE guidelines on familial breast cancer state that BRCA1/2 carriers 
should undergo annual mammograms and breast magnetic resonance 
imaging (MRI) from ages 30 – 50 and after 50 years of age individualised 
arrangements should be devised due to a lack of trial data. We decided to 
advise our BRCA1/2 carriers to have 18 monthly mammograms if > 50 years 
of age.  
 
Specific protocols were developed for women opting for risk reducing surgery 
based on these guidelines and on published data. Our protocol for risk 
reducing mastectomy ensured that all possible breast reconstruction options 
(immediate and delayed) were discussed and demonstration material and 
pictures were used with women who opted for an appointment with our breast 
surgeon with specialist/oncoplastic and breast reconstructive skills. The risk of 
breast cancer being diagnosed following bilateral risk-reducing mastectomy 
was discussed. Women were offered peer support with access to other 
women who had undergone the procedure. Pre-operative counselling by our 
psychologist about psychosocial and sexual consequences of bilateral risk-
reducing mastectomy was undertaken during attendance at the MDOSC or 
recommended to be undertaken after the appointment for women opting for 
risk reducing mastectomies. 
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Women opting for the removal of their ovaries and fallopian tubes and their 
treating gynaecologists were provided with a protocol recommending RRSO 
with laparoscopic inspection of the abdomino-pelvic cavity, peritoneal 
washings and routine endometrial curettage for women on Tamoxifen. Serial 
slicing (2mm) of the fallopian tubes and ovaries was recommended for 
histopathological processing. Furthermore, prescription of hormonal 
replacement therapy for premenopausal women who had not had breast 
cancer was suggested until the age of 50. 
 
Uptake and satisfaction with the new service (to be reported elsewhere) was 
evaluated during 24 months, including numbers of individuals undergoing 
breast and ovarian surveillance, adherence to the recommended surveillance, 
numbers of individuals opting for and outcome of risk reducing surgery 
surgery, participation in clinical trials, number and stage of newly diagnosed 
cancers and their method of detection. Individuals who attended the MDOSC 
were contacted by mail/telephone 12 and 24 months after attending the 
MDOSC and a follow-up appointment was offered. Information on 
breast/ovarian surveillance and risk reducing surgery was collected and 
reports and histology reports were obtained prior to the MDOSC. All available 
data until the end of September 2008 were included in this report. 
 
Statistical analysis 
The data for uptake of interventions before as against after the start of the 
MDOSC were analysed using Chi-squared tests (2 x 2 contingency) to 
examine differences. Pearson’s chi-squared (with Yates’ continuity correction 
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and 1 degree of freedom) and corresponding p-values, significance levels, 
and odds ratios with 95% confidence intervals were calculated.  
 
 
RESULTS 
Patient characteristics:  Two hundred and eighty eight individuals were 
invited to attend the MDOSC between February 2006 and February 2008. 172 
(60%) chose to attend. Thirty five (12%) of individuals did not want to attend 
the MDOSC at that time but asked for an appointment in one year’s time. 
Thirty five (12%) did not respond and 46 (15%) declined our invitation. The 
reasons given were as follows: They were too old to travel or not feeling well, 
the MDOSC was too far away from where they lived, they had already had all 
the risk reducing surgery presently available or they had nothing to discuss. 
Characteristics of patients attending the MDOSC are summarized in Table 2. 
The median time between receiving the genetic test result and attending the 
MDOSC was 32 months with a range of 1-147 months. 
 
Breast and ovarian surveillance: Twenty five (15%) of the 164 women seen 
in the MDOSC had undergone risk reducing breast surgery prior to attending 
the clinic. Sixteen women were too young to be eligible for breast surveillance 
according to the NICE guidelines on familial breast cancer. Table 3 details the 
type and frequency of breast surveillance that the 123 women, eligible for 
breast surveillance under the national guidelines, received prior to attending 
the MDOSC. One hundred and twenty three women were eligible for 
mammograms. Seventy six of 123 women were between 30 and 50 years old 
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and therefore eligible for annual mammograms and breast MRI scans. Twenty 
three of 123 (19%) did not undergo mammograms before attending the 
MDOSC and 67/76 (88%) of women did not undergo breast MRI scans before 
attending the MDOSC. In 17/123 (14%) of women the frequency of breast 
surveillance was altered to comply with the NICE guidelines on surveillance 
for familial breast cancer after attending the MDOSC. Two mammographically 
detected breast cancers were observed between February 2006 and 
September 2008 but no interval breast cancers. 
 
As there is no ovarian surveillance of proven efficacy, ovarian surveillance 
was only offered as part of the UK Familial Ovarian Cancer Screening Study 
=UKFOCSS (5) where women ≥ 35 years of age undergo yearly vaginal 
ultrasounds as well 4-monthly CA-125 serum measurements. Seventy nine of 
164 (48%) of women were ineligible for the study (30 women were < 35 years 
of age, 9 women had been diagnosed with ovarian cancer and 40 women had 
undergone risk reducing surgery to remove their ovaries prior to attending the 
MDOSC). Of the remaining 85 women, 39 received either yearly abdominal or 
transvaginal ultrasound and/or yearly CA-125 serum measurements prior to 
attending the MDOSC. Twenty six of these 39 women chose to undergo 
ovarian surveillance in the future within the UKFOCSS study and a further 32 
women joined the study after attending the MDOSC. 
 
Risk reducing surgery: Eighty eight (54%) of 164 women had been 
diagnosed with breast cancer, 20 (12%) women had undergone a contra 
lateral and 5 (4%) women had undergone a bilateral risk reducing mastectomy 
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prior to attending the MDOSC. After attending the MDOSC, 33 (24%) 
seriously considered risk reducing mastectomy, 12 (9%) decided to have a 
risk reducing mastectomy and 13 (9%) of 139 women had undergone the 
procedure by September 2008 (see Table 3).  
 
As outlined above, 79 women were ineligible for RRSO. For details of patient 
numbers undergoing surgery and histological findings see Table 4 and for 
details of types of operations and histo-pathological processing in the two 
groups of women see Table 5.  
 
Clinical trial enrolment 
Individuals attending the MDOSC were offered enrolment into the following 
trials: UKFOCCS(5), Epidemiological Study of Familial Breast 
Cancer=EMBRACE(6), Prevention and Observation of Surgical 
Endpoints=PROSE (7), Identification of Men with a Genetic Predisposition to 
Prostate Cancer: Targeted Screening in BRCA1/2 Mutation Carriers and 
Controls=IMPACT (8), International Breast Cancer Intervention Study=IBIS-2 
(9) and the BRCA trial (10). For details of patients recruited to each trial see 
Figure 1. All 172 pts attending the MDOSC were eligible for the EMBRACE 
trial: 46 (27%) had already been recruited prior to attending the MDOSC. Of 
the remaining 126 patients, 2 declined an appointment with the research 
nurse, 23 did not send the questionnaire and consent form back handed to 
them during MDOSC attendance resulting in an enrolment of 101 (80%) of 
patients attending the MDOSC as shown in Table 5. Recruitment to 
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UKFOCCS also improved significantly from 5 patients before to 46 patients 
after attending the MDOSC (p<0.001) as shown in Table 5.  
 
DISCUSSION 
Individuals who undergo genetic testing for BRCA1/2 mutations receive pre- 
and post-test counselling by genetic health care professionals as required by 
international guidelines4, American Society of Clinical Oncology Policy 
Statement Update (11). Individuals with a pathogenic BRCA1/2 mutation 
usually discuss their cancer risk management with a genetic health care 
professional at one or several post-test counselling sessions and if they opt 
for risk reducing procedure, a referral is made to the respective specialist 
surgeon. 
 
The most important decision for women with a BRCA1/2 mutation is whether 
to consider risk reducing surgery. Risk reducing mastectomy for example is 
very effective in reducing the risk of breast cancer by ≥ 90% Bernadette et al 
(12), while RRSO can reduce ovarian/fallopian tube cancer risk by 95% and 
breast cancer risk by up to 50% in premenopausal women Rebbeck et al (13), 
Kauuf et al (14). Other options include breast surveillance, chemoprevention 
and participation in ovarian cancer screening trials. However, risk reducing 
breast surgery is a highly complex procedure from medical, physical and 
psychological viewpoints and needs careful consideration and counselling and 
RRSO can result in significant symptoms in women unable to take HRT. 
Therefore, we reasoned that a one-stop clinic providing BRCA1/2 carriers with 
an opportunity to discuss all cancer management options and receive 
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psychological support and counselling at the same time, combined with a 
preceding multidisciplinary meeting of all health care professionals to devise 
an individualized cancer management strategy, would enable BRCA1/2 
carriers to make fully informed and supported decisions on issues pertinent to 
their BRCA1/2 carrier status. 
 
The majority of invited BRCA1/2 carriers chose to attend the MDOSC. The 
most popular risk reducing procedure was RRSO with a significant increase in 
uptake (see Table 5). After attending the MDOSC, 40 (47%) of 85 women ≥ 
35 years with intact ovaries decided to undergo this procedure and 33 (39%) 
of 85 women were seriously considering it. These findings demonstrate that 
the majority of women choosing to attend the MDOSC want to reduce their 
ovarian/fallopian tube cancer risk. The decision to opt for surgery may also be 
influenced by the awareness that RRSO, if performed premenopausally, 
delivers additional benefits with regard to breast cancer risk reduction.  
 
The MDOSC provided women with crucial information relevant to their chosen 
surgery and empowered them to discuss the appropriate approach with their 
surgeon. Our MDOSC devised protocols have also improved effective 
communication with other surgical teams as evidenced by an improvement in 
surgical protocol compliance. 6/40 (15%) women undergoing risk reducing 
ovarian surgery before attending the MDOSC did not have their fallopian 
tubes removed compared to only 1/28 (3%) women undergoing RRSO after 
attending the MDOSC. Furthermore, the number of women who had 
peritoneal washings and 2 mm slicing of their fallopian tubes and ovaries rose 
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from 9/36 (25%) and 5/36 (14%) respectively before attending the MDOSC to 
18/27 (67%) and 17/27 (63%) respectively after attending the MDOSC. Our 
findings highlight the importance of providing surgeons performing a RRSO 
with a protocol tailored to the biology of BRCA1/2 associated ovarian/tubal 
malignancies as the lifetime risk of fallopian tube cancers Brose et al (15), Piek 
et al (16) in BRCA1/2 carriers is much higher than in the general population 
and as a recent study showed that the fimbrial end of the fallopian tube 
appears to be the dominant site of origin for early malignancies on BRCA1/2 
carriers Callahan et al (17). Furthermore, as up to 2.5% of BRCA1/2 mutation 
carrying women undergoing an RRSO have an occult malignancy Powell et al 
(18), rigorous operative and pathological sampling is of crucial importance.  
 
Sixteen percent of our BRCA1/2 carriers chose risk reducing breast surgery 
prior to attending and 42% either seriously considered (24%) or decided to 
undergo (18%) risk reducing mastectomy after attending the MDOSC. 
Although the uptake of risk reducing mastectomy in BRCA1/2 mutation 
carrying women varies widely among different countries Metcalfe et al (19), 
this percentage is within the percentages reported for the UK20. Interestingly, 
in contrast to RRSO, MDOSC attendance did not result in an increased 
uptake of risk reducing breast surgery (see Table 5). 
 
Despite having undergone pre- and post-test genetic counselling, 19% and 
88% of women eligible for breast surveillance under the national guidelines 
did not receive mammograms and breast MRI scans respectively before 
attending the MDOSC and a further 14% had their breast surveillance 
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schedules altered to adhere to national guidelines after attending the MDOSC. 
These findings underline the importance of a structured follow-up of 
individuals carrying a cancer predisposing gene mutation to ensure that 
surveillance recommendations are put into clinical practice. However, it should 
be noted that although annual MRI scans have been recommended for BRCA 
carriers since 2006 (4), access to this surveillance currently depends on the 
availability of facilities and expertise, and funding agreement from the patient’s 
Primary Care Trust. This situation will be rectified once the National Cancer 
Reform Strategy (21) is implemented across England and Wales.  
 
As there are many unanswered research questions in inherited breast/ovarian 
cancer, BRCA1/2 carriers should be given the opportunity to participate in 
clinical trials. Like the multidisciplinary follow up BRCA1/2 carrier clinic 
currently offered at the Royal Marsden Hospital in London Bancroft et al (22), 
our MDOSC significantly increased enrolment into research trials. 
 
In conclusion, attendance at our MDOSC resulted in a significant 
improvement of breast and ovarian cancer risk management in our BRCA1/2 
carriers. Based on our results, Guy’s and St Thomas Foundation Trust have 
decided to fund the MDOSC as a clinical service. 
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Figure Legend 
Figure 1: Number of patients enrolled in clinical trials before and after 
attending the MDOSC. 
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